Summarized & reviewed by The Peptide Dispatch Editorial Team · Last reviewed August 5, 2026
Most of the markers worth writing about follow the same shape. Low is bad, high is bad, or the risk climbs steadily in one direction and the only question is where the useful threshold sits. You can hold one idea in your head and be roughly right. IGF-1 does not work that way, and that is the entire reason it is worth a careful read. Insulin-like growth factor 1 is the downstream signal of the…
This dispatch covers IGF-1 Is the Rare Marker Where Optimizing Upward Has a Documented Cost in the metabolic research category, authored by The Peptide Dispatch Editorial Team. Estimated reading time: 9 minutes. The Peptide Dispatch curates peer-reviewed peptide research for self-directed learners. All summaries are presented for Research Use Only and do not constitute medical advice.
Most of the markers worth writing about follow the same shape. Low is bad, high is bad, or the risk climbs steadily in one direction and the only question is where the useful threshold sits. You can hold one idea in your head and be roughly right.
IGF-1 does not work that way, and that is the entire reason it is worth a careful read.
Insulin-like growth factor 1 is the downstream signal of the growth hormone axis. The pituitary releases growth hormone in pulses, mostly at night, which makes growth hormone itself nearly useless to measure from a single morning draw. The liver responds by producing IGF-1, which circulates bound to carrier proteins and stays relatively stable across the day. So IGF-1 became the practical readout of an axis that is otherwise difficult to sample. It is the number clinicians look at when they want to know what growth hormone has actually been doing.
It is also the number that gets treated, in a lot of informal discussion, as something to push up. That framing does not survive contact with the cohort data.
The largest analysis comes from UK Biobank. Investigators included 380,997 participants who had a serum IGF-1 measurement and no history of cancer, cardiovascular disease, or diabetes at baseline, then followed them for a median of 8.8 years, recording 10,753 deaths. Results were published in the European Journal of Endocrinology (DOI).
Using restricted cubic splines, the relationship between IGF-1 and mortality came out U-shaped. Compared with the fifth decile, the lowest decile carried a 39 percent higher risk of all-cause death (95% CI 29 to 50 percent), a 20 percent higher risk of cancer death, and a 39 percent higher risk of cardiovascular death.
The top of the range was not neutral. The highest decile carried a 17 percent higher risk of all-cause death (95% CI 7 to 28 percent) and a 38 percent higher risk of cardiovascular death (95% CI 11 to 71 percent). The associations held through stratified and sensitivity analyses.
Read that again with the framing reversed. In a cohort of nearly 400,000 people screened free of major disease at baseline, being in the top ten percent of IGF-1 was associated with meaningfully more death than sitting in the middle.
The Osteoporotic Fractures in Men study in Sweden measured IGF-1 in 2,901 men with a mean age of 75 and followed them six years, with mortality captured from central registers and no loss to follow-up (DOI).
The U-shape appeared again. Both the lowest and the highest quintile, compared with the middle three, were associated with increased cancer mortality, with hazard ratios of 1.86 and 1.90 respectively. Cardiovascular mortality behaved differently. Only low IGF-1 was associated with it, at a hazard ratio of 1.48. The associations persisted after excluding men who died in the first two years, which is the standard check for reverse causation from occult illness already present at baseline.
The Longitudinal Aging Study Amsterdam followed 1,273 older adults for 11.6 years (DOI). Lowest quintile versus middle carried a hazard ratio of 1.28 for all-cause death. For cardiovascular death specifically, both low-normal and high-normal values more than doubled risk, at hazard ratios of 2.39 and 2.03.
Note the phrasing in that last one. Low-normal and high-normal. Both inside the reference interval.
Observational cohorts show association. They cannot, on their own, tell you whether moving the number would move the outcome. That limitation applies to almost every marker discussed in this publication, and it is usually where the honest analysis has to stop.
IGF-1 is unusual in that there is genetic evidence pointing at the same conclusion from a different direction.
A Mendelian randomisation study published in Diabetologia used 416 SNPs associated with IGF-1 levels in 358,072 UK Biobank participants, then tested genetically predicted IGF-1 against outcome consortia covering type 2 diabetes (74,124 cases), coronary artery disease (60,801 cases), heart failure, atrial fibrillation, and ischaemic stroke (DOI).
Genetic predisposition to higher IGF-1 was associated with higher risk of type 2 diabetes, at an odds ratio of 1.14 per standard deviation increment (95% CI 1.05 to 1.24), and higher risk of coronary artery disease at 1.09 (95% CI 1.02 to 1.16). The coronary association weakened after adjustment for type 2 diabetes, which suggests part of the effect runs through diabetes rather than around it. Heart failure, atrial fibrillation, and stroke showed limited evidence of association.
Because genetic variants are assigned at conception and are not shuffled by lifestyle, illness, or the behaviour that leads someone to get tested, this design is much harder to explain away as reverse causation. It is not proof, and Mendelian randomisation carries its own well-documented assumptions, but it is a meaningfully different line of evidence arriving at a compatible answer on the upper end of the range.
The counterexamples deserve equal space.
A UK Biobank analysis of 414,923 participants examined adult height against incidence and mortality across 24 cancer sites, and specifically tested whether IGF-1 concentration moderated the height and cancer relationship (DOI). Height was associated with several cancers in a sex-specific pattern. The strength of that association did not differ by IGF-1 concentration. The authors found no strong evidence that IGF-1 was the mechanism.
That matters because the tidy story people tell about IGF-1 and cancer usually runs through exactly that pathway. One large, direct test of it came back negative.
The mortality associations are also modest in absolute terms. A hazard ratio of 1.17 for the top decile in a cohort with an 8.8-year median follow-up is a real signal and a small one. It is not the difference between health and disease in an individual person.
Two practical issues make single IGF-1 values harder to interpret than most.
The first is assay variability. IGF-1 is measured by several different methods, and manufacturers typically supply generalised reference values while recommending that individual laboratories establish their own. A cross-sectional study of 255 healthy Korean men aged 19 to 40 built institution-specific reference ranges precisely because of this problem (DOI). A value from one lab is not cleanly comparable to a value from another.
The second is that the same study documented significant seasonal variation, with differences between spring, autumn, and winter groups. That is not a subtlety you can ignore when comparing a summer draw to a winter one.
Layered on top is the age dependence. IGF-1 falls steadily across adult life, so a raw number means very little without knowing which age-adjusted interval it is being read against. Most laboratories report it against an age band for this reason, and that band is the relevant comparison, not a generic adult range.
No trial has demonstrated that deliberately raising or lowering IGF-1 in a healthy adult improves survival. The cohort data describe where risk sits across a population distribution. That is not the same as a validated personal target, and treating a percentile as a goal is the standard error people make with markers of this kind.
IGF-1 is also not a diagnostic test on its own. A high value prompts questions about the growth hormone axis, nutritional state, insulin signalling, and liver function. A low value prompts a different set, including caloric intake, protein status, thyroid function, liver disease, and pituitary function. Neither result is an answer.
And the two ends of the curve are almost certainly not the same phenomenon wearing different signs. Low IGF-1 in an older adult often reflects poor nutritional and inflammatory status, which is a marker of frailty rather than a cause of it. High IGF-1 appears, from the genetic data, to carry some independent metabolic cost. Collapsing both into one tidy narrative about optimal levels obscures more than it explains.
If IGF-1 appears on a panel, three questions do most of the work.
Which age-adjusted interval is it being read against, and what percentile does it sit at within that band, rather than simply whether it cleared the reference range. Whether the trend across serial draws is stable, and if not, whether the draws came from the same laboratory and the same season, because otherwise the trend may be an artefact of the assay. And whether anything in the broader panel, particularly fasting insulin, glucose, and liver enzymes, is moving in the same direction, since the genetic evidence points at a metabolic pathway rather than an isolated one.
Anyone using compounds that act on the growth hormone axis has a further reason to look, because IGF-1 is the standard monitoring marker for that axis and the upper end of the range is not a neutral place to sit. What the appropriate ceiling is, and whether any of it applies to an individual case, is a clinical judgement that requires a licensed clinician who can see the whole picture.
The general point survives all of the caveats. IGF-1 is one of the few markers on a comprehensive panel where the published evidence says the middle is the destination, and where pushing the number higher has a documented cost attached rather than an assumed benefit.
The Peptide Dispatch publishes research summaries for educational purposes. This material describes what the published literature reports about laboratory markers and physiology. It is not medical advice, it is not a diagnosis, and it does not recommend or endorse any treatment, product, or provider. Laboratory results require interpretation by a licensed clinician in the context of your individual history. Always discuss testing and treatment decisions with a qualified healthcare professional.
Research summaries in this article are based on articles retrieved from PubMed.
Educational content — not medical advice. Effects described are drawn from cited research in study subjects.